Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-12-12 21:57 UTC (UTC+2h)

Patient population for bioequivalence study [Regulatives / Guidelines]

posted by pash413 - India, 2017-10-04 13:44  - Posting: # 17855
Views: 859

Dear All
We are planning to conduct a bioequivalence study in patient population for USFDA submission.

As per product label, the drug is used in three indications (i.e. diseases)

Out of three indication, patients comprise of two indication are difficult to recruit, because of disease criticality & severity. However for third indication, patients are abundantly available for the enrollment in to the BE study.

Considering the above fact, is it necessary to conduct bioequivalence study in all eligible patient population as per label or we can recruit only patients for third indication. Will there be any regulatory concerns in term of BE acceptance, product approval & getting marketing authorization for all indication.

Kindly share your view.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,555 Posts in 3,758 Threads, 1,089 registered users;
32 users online (0 registered, 32 guests).

Enlightenment is man’s emergence from his self-imposed nonage
for which he himself was responsible.
Nonage is the inability to use one’s own intellect
without the direction of another.    Immanuel Kant

BEBAC Ing. Helmut Schütz